Venrock Adviser, LLC
Venrock Adviser, LLC reported 33 positions worth $3.30B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: APOGEE THERAPEUTICS INC (34.2%).
| # | Symbol | Company | Type | Value ↓ | % Port. | Shares | 1Y | YTD |
|---|---|---|---|---|---|---|---|---|
| ▸ 1 | 03770N101 | SH | $1.13B | 34.18% | 8,493,321 | — | — | |
| ▸ 2 | ORKA | SH | $394.8M | 11.97% | 4,148,428 | — | — | |
| ▸ 3 | ERAS | SH | $327.8M | 9.94% | 17,891,812 | — | — | |
| ▸ 4 | SYRE | SH | $265.0M | 8.04% | 2,985,448 | — | — | |
| ▸ 5 | DNTH | SH | $115.0M | 3.49% | 1,180,000 | — | — | |
| ▸ 6 | OCUL | SH | $101.6M | 3.08% | 10,346,926 | — | — | |
| ▸ 7 | 36322Q206 | SH | $93.7M | 2.84% | 3,603,595 | — | — | |
| ▸ 8 | SVRA | SH | $90.8M | 2.75% | 14,745,943 | — | — | |
| ▸ 9 | JBIO | SH | $71.6M | 2.17% | 3,220,364 | — | — | |
| ▸ 10 | COGT | SH | $63.6M | 1.93% | 1,642,166 | — | — |
The free plan shows the top 10 positions. The remaining 23 positions, the full portfolio and quarter changes unlock with Pro.
Pro Feature
This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.
Upgrade to ProRead the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Venrock Adviser, LLC hold as of Q2 2026?
Venrock Adviser, LLC reported 33 positions worth $3.30B in its Q2 2026 13F filing. Largest positions: APOGEE THERAPEUTICS INC (34.2%), ORKA (12.0%), ERAS (9.9%), SYRE (8.0%) and DNTH (3.5%).
What did Venrock Adviser, LLC buy in Q2 2026?
No previous quarter is available yet; the comparison appears with the next filing.
What did Venrock Adviser, LLC sell in Q2 2026?
No previous quarter is available yet.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.